Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

NCT06282159 is registered in ClinicalTrials.gov with Dianthus Therapeutics as lead sponsor.

NCT NCT06282159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06282159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Blinded, Placebo-Controlled, Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
Lead sponsor
Dianthus Therapeutics
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 23, 2024
Completion date
October 31, 2028
Enrollment
65 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis, generalized